Helicobacter pylori is listed as a carcinogen, a "hot spot" on the interactive platform of many listed companies
China-Singapore Jingwei, January 6th (Wang Yuling) Recently, Helicobacter pylori has been listed as a carcinogen and has attracted public attention.
According to media reports, the 15th carcinogen report issued by the U.S. Department of Health and Human Services (HHS) shows that Helicobacter pylori is classified as a "clear carcinogen."
According to a CCTV news report, China's Helicobacter pylori infection rate varies significantly in different regions, with an average infection rate of 59% and a child infection rate of 40%.
Affected by the news, the share price of Helicobacter pylori concept rose accordingly.
According to Flush iFinD, as of the close of the market on January 6, the sector rose 7.42%. Among the 11 concept stock companies, only Yueyang Xingchang received green, and the rest were all red. Ketuo Bio, Asia-Pacific Pharmaceuticals, and Juneyao Health had daily limit.
Sino-Singapore Jingwei noticed that a number of listed companies have begun to "snap" Helicobacter pylori hot spots, responding to investors' questions about Helicobacter pylori.
On January 5, SDIC Zhonglu said on the investor interaction platform SSE e Interactive that the anti-Helicobacter pylori-related products are still in the research and development stage, and there are certain uncertainties in the commercial prospects, reminding investors to pay attention to investment risks.
According to public information, SDIC Zhonglu is mainly engaged in the production and sales of concentrated fruit and vegetable juices and beverages, with the main product being concentrated apple juice.
On January 6, Ruizhi Pharmaceutical introduced on the investor interactive platform Interactive Yi, the company’s fructooligosaccharides and galactooligosaccharides are typical high-quality prebiotics. At present, foreign studies have shown that prebiotics can assist in the elimination of Helicobacter pylori drugs to improve Clearance rate, but the company has not conducted relevant research, and it is currently unable to confirm whether it can cooperate with drugs to treat Helicobacter pylori.
According to public information, Ruizhi Pharmaceutical is a pharmaceutical R&D outsourcing service organization (CRO+CDMO business).
On the same day, Blue Biotech confirmed e Interactive's response on the investor interactive platform that the company's anti-H. pylori probiotics are still in the early stage of research and development, and there is great uncertainty in the development of research and development, and there is a risk of research and development failure.
It is currently impossible to confirm whether it can be combined with drugs to treat Helicobacter pylori, and a large number of clinical trials are needed to confirm it later.
According to publicly available information, Blue Bio is a biotechnology company whose main business is the production, research and development and sales of enzyme preparations and microecological preparations.
(Zhongxin Jingwei APP)
All rights reserved by Sino-Singapore Jingwei. Without written authorization, no unit or individual may reprint, extract or use it in other ways.